Global Anticoagulation Therapy

Anticoagulation Therapy Comprehensive Study by Application (Venous Thromboembolism, Deep Vein Thrombosis, Coronary Artery Disease, Heart Attack), Route of Administration (Oral, Parenteral), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online, Others), End-user (Hospitals, Clinics, Homecare, Ambulatory Surgical Centres, Others), Drug Class (Novel Oral Anticoagulants (NOACs), Heparin & LMWH, Vitamin K Antagonists, Others) Players and Region - Global Market Outlook to 2028

Anticoagulation Therapy Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Anticoagulation Therapy Market?

Anticoagulant therapy is the most widely used treatment for venous thromboembolism (VTE), a term referring to blood clots in the veins. Venous thromboembolism (VTE) is the third leading vascular diagnosis after a heart attack and stroke. VTE affecting between 300,000 to 600,000 Americans every year. In anticoagulation therapy, anticoagulants, a chemical substance that prevents or reduces coagulation of blood, are used to treat and prevent blood clots that may occur in the patient's blood vessels. The factors such as Increased Prevalence of Venous Thromboembolism, Deep Vein Thrombosis, and Heart Diseases among People as well as the Development of New Diagnostic Centres and Hospitals in Developing Countries are the key driving factors for the global Anticoagulation Therapy market. In addition, Increased Adoption of DOACs to Prevent VTE also fueling market growth. However, Uncertainty Regarding Assessment of Drug Levels and the High Risk of Malfunctions like Increased Bleeding may hamper the market growth.

Highlights from Anticoagulation Therapy Market Study
AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledGlaxoSmithKline plc (United Kingdom), Pfizer, Inc. (United States), Abbott Laboratories (United States), Baxter International Inc. (United States), AstraZeneca plc (United Kingdom), Bayer AG (Germany), Merck & Co., Inc. (United States), Eli Lilly and Company (United States), Bristol-Myers Squibb Company (United States), Genentech Inc. (United States), Sanofi S.A. (France) and Novartis International AG (Switzerland)


The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Anticoagulation Therapy market throughout the forecasted period.

GlaxoSmithKline plc (United Kingdom), Pfizer, Inc. (United States), Abbott Laboratories (United States), Baxter International Inc. (United States), AstraZeneca plc (United Kingdom), Bayer AG (Germany), Merck & Co., Inc. (United States), Eli Lilly and Company (United States), Bristol-Myers Squibb Company (United States), Genentech Inc. (United States), Sanofi S.A. (France) and Novartis International AG (Switzerland) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are BioVascular Inc. (United Kingdom) and C.H. Boehringer Sohn AG & Ko. KG (Germany).

Anticoagulation Therapy Market Segmentation:
ScopeSub-Segments
Application / End UserVenous Thromboembolism, Deep Vein Thrombosis, Coronary Artery Disease and Heart Attack
Route of AdministrationOral,Parenteral
Distribution ChannelHospital Pharmacies,Retail Pharmacies,Online,Others
End-userHospitals,Clinics,Homecare,Ambulatory Surgical Centres,Others
Drug ClassNovel Oral Anticoagulants (NOACs),Heparin & LMWH,Vitamin K Antagonists,Others


On the basis of geography, the market of Anticoagulation Therapy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increased Adoption of DOACs to Prevent VTE

Market Growth Drivers:
Increased Prevalence of Venous Thromboembolism, Deep Vein Thrombosis and Heart Diseases among People and Development of New Diagnostic Centres and Hospitals in Developing Countries

Challenges:
High Risk of Malfunctions like Increased Bleeding

Restraints:
Uncertainty Regarding Assessment of Drug Levels

Opportunities:
Growth in the Geriatric Population, Increasing Number of People Suffering from Obesity and Growing Healthcare Industry Worldwide

Key Target Audience
Anticoagulation Therapy Drug Manufacturers, Distributors, Emerging Companies, Research Professionals and End-users

Market Leaders & Development Strategies
On 30th July 2019, Pfizer Inc. had announced the successful completion of its acquisition of Array BioPharma Inc., advancing breakthrough science for the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need.
In December 2019, The FDA has approved the first two generics of Pfizer and Bristol-Myers Squibb’s blockbuster anticoagulant drug Eliquis, from Micro Labs and Mylan.


Report Objectives / Segmentation Covered

By Application
  • Venous Thromboembolism
  • Deep Vein Thrombosis
  • Coronary Artery Disease
  • Heart Attack
By Route of Administration
  • Oral
  • Parenteral

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online
  • Others

By End-user
  • Hospitals
  • Clinics
  • Homecare
  • Ambulatory Surgical Centres
  • Others

By Drug Class
  • Novel Oral Anticoagulants (NOACs)
  • Heparin & LMWH
  • Vitamin K Antagonists
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Venous Thromboembolism, Deep Vein Thrombosis and Heart Diseases among People
      • 3.2.2. Development of New Diagnostic Centres and Hospitals in Developing Countries
    • 3.3. Market Challenges
      • 3.3.1. High Risk of Malfunctions like Increased Bleeding
    • 3.4. Market Trends
      • 3.4.1. Increased Adoption of DOACs to Prevent VTE
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Anticoagulation Therapy, by Application, Route of Administration, Distribution Channel, End-user, Drug Class and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Anticoagulation Therapy (Value)
      • 5.2.1. Global Anticoagulation Therapy by: Application (Value)
        • 5.2.1.1. Venous Thromboembolism
        • 5.2.1.2. Deep Vein Thrombosis
        • 5.2.1.3. Coronary Artery Disease
        • 5.2.1.4. Heart Attack
      • 5.2.2. Global Anticoagulation Therapy by: Route of Administration (Value)
        • 5.2.2.1. Oral
        • 5.2.2.2. Parenteral
      • 5.2.3. Global Anticoagulation Therapy by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Online
        • 5.2.3.4. Others
      • 5.2.4. Global Anticoagulation Therapy by: End-user (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Clinics
        • 5.2.4.3. Homecare
        • 5.2.4.4. Ambulatory Surgical Centres
        • 5.2.4.5. Others
      • 5.2.5. Global Anticoagulation Therapy by: Drug Class (Value)
        • 5.2.5.1. Novel Oral Anticoagulants (NOACs)
        • 5.2.5.2. Heparin & LMWH
        • 5.2.5.3. Vitamin K Antagonists
        • 5.2.5.4. Others
      • 5.2.6. Global Anticoagulation Therapy Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Anticoagulation Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline plc (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Abbott Laboratories (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Baxter International Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. AstraZeneca plc (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bayer AG (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Merck & Co., Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Eli Lilly and Company (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bristol-Myers Squibb Company (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Genentech Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Sanofi S.A. (France)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Novartis International AG (Switzerland)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Anticoagulation Therapy Sale, by Application, Route of Administration, Distribution Channel, End-user, Drug Class and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Anticoagulation Therapy (Value)
      • 7.2.1. Global Anticoagulation Therapy by: Application (Value)
        • 7.2.1.1. Venous Thromboembolism
        • 7.2.1.2. Deep Vein Thrombosis
        • 7.2.1.3. Coronary Artery Disease
        • 7.2.1.4. Heart Attack
      • 7.2.2. Global Anticoagulation Therapy by: Route of Administration (Value)
        • 7.2.2.1. Oral
        • 7.2.2.2. Parenteral
      • 7.2.3. Global Anticoagulation Therapy by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Online
        • 7.2.3.4. Others
      • 7.2.4. Global Anticoagulation Therapy by: End-user (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Clinics
        • 7.2.4.3. Homecare
        • 7.2.4.4. Ambulatory Surgical Centres
        • 7.2.4.5. Others
      • 7.2.5. Global Anticoagulation Therapy by: Drug Class (Value)
        • 7.2.5.1. Novel Oral Anticoagulants (NOACs)
        • 7.2.5.2. Heparin & LMWH
        • 7.2.5.3. Vitamin K Antagonists
        • 7.2.5.4. Others
      • 7.2.6. Global Anticoagulation Therapy Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Anticoagulation Therapy: by Application(USD Million)
  • Table 2. Anticoagulation Therapy Venous Thromboembolism , by Region USD Million (2017-2022)
  • Table 3. Anticoagulation Therapy Deep Vein Thrombosis , by Region USD Million (2017-2022)
  • Table 4. Anticoagulation Therapy Coronary Artery Disease , by Region USD Million (2017-2022)
  • Table 5. Anticoagulation Therapy Heart Attack , by Region USD Million (2017-2022)
  • Table 6. Anticoagulation Therapy: by Route of Administration(USD Million)
  • Table 7. Anticoagulation Therapy Oral , by Region USD Million (2017-2022)
  • Table 8. Anticoagulation Therapy Parenteral , by Region USD Million (2017-2022)
  • Table 9. Anticoagulation Therapy: by Distribution Channel(USD Million)
  • Table 10. Anticoagulation Therapy Hospital Pharmacies , by Region USD Million (2017-2022)
  • Table 11. Anticoagulation Therapy Retail Pharmacies , by Region USD Million (2017-2022)
  • Table 12. Anticoagulation Therapy Online , by Region USD Million (2017-2022)
  • Table 13. Anticoagulation Therapy Others , by Region USD Million (2017-2022)
  • Table 14. Anticoagulation Therapy: by End-user(USD Million)
  • Table 15. Anticoagulation Therapy Hospitals , by Region USD Million (2017-2022)
  • Table 16. Anticoagulation Therapy Clinics , by Region USD Million (2017-2022)
  • Table 17. Anticoagulation Therapy Homecare , by Region USD Million (2017-2022)
  • Table 18. Anticoagulation Therapy Ambulatory Surgical Centres , by Region USD Million (2017-2022)
  • Table 19. Anticoagulation Therapy Others , by Region USD Million (2017-2022)
  • Table 20. Anticoagulation Therapy: by Drug Class(USD Million)
  • Table 21. Anticoagulation Therapy Novel Oral Anticoagulants (NOACs) , by Region USD Million (2017-2022)
  • Table 22. Anticoagulation Therapy Heparin & LMWH , by Region USD Million (2017-2022)
  • Table 23. Anticoagulation Therapy Vitamin K Antagonists , by Region USD Million (2017-2022)
  • Table 24. Anticoagulation Therapy Others , by Region USD Million (2017-2022)
  • Table 25. South America Anticoagulation Therapy, by Country USD Million (2017-2022)
  • Table 26. South America Anticoagulation Therapy, by Application USD Million (2017-2022)
  • Table 27. South America Anticoagulation Therapy, by Route of Administration USD Million (2017-2022)
  • Table 28. South America Anticoagulation Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 29. South America Anticoagulation Therapy, by End-user USD Million (2017-2022)
  • Table 30. South America Anticoagulation Therapy, by Drug Class USD Million (2017-2022)
  • Table 31. Brazil Anticoagulation Therapy, by Application USD Million (2017-2022)
  • Table 32. Brazil Anticoagulation Therapy, by Route of Administration USD Million (2017-2022)
  • Table 33. Brazil Anticoagulation Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 34. Brazil Anticoagulation Therapy, by End-user USD Million (2017-2022)
  • Table 35. Brazil Anticoagulation Therapy, by Drug Class USD Million (2017-2022)
  • Table 36. Argentina Anticoagulation Therapy, by Application USD Million (2017-2022)
  • Table 37. Argentina Anticoagulation Therapy, by Route of Administration USD Million (2017-2022)
  • Table 38. Argentina Anticoagulation Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 39. Argentina Anticoagulation Therapy, by End-user USD Million (2017-2022)
  • Table 40. Argentina Anticoagulation Therapy, by Drug Class USD Million (2017-2022)
  • Table 41. Rest of South America Anticoagulation Therapy, by Application USD Million (2017-2022)
  • Table 42. Rest of South America Anticoagulation Therapy, by Route of Administration USD Million (2017-2022)
  • Table 43. Rest of South America Anticoagulation Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 44. Rest of South America Anticoagulation Therapy, by End-user USD Million (2017-2022)
  • Table 45. Rest of South America Anticoagulation Therapy, by Drug Class USD Million (2017-2022)
  • Table 46. Asia Pacific Anticoagulation Therapy, by Country USD Million (2017-2022)
  • Table 47. Asia Pacific Anticoagulation Therapy, by Application USD Million (2017-2022)
  • Table 48. Asia Pacific Anticoagulation Therapy, by Route of Administration USD Million (2017-2022)
  • Table 49. Asia Pacific Anticoagulation Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 50. Asia Pacific Anticoagulation Therapy, by End-user USD Million (2017-2022)
  • Table 51. Asia Pacific Anticoagulation Therapy, by Drug Class USD Million (2017-2022)
  • Table 52. China Anticoagulation Therapy, by Application USD Million (2017-2022)
  • Table 53. China Anticoagulation Therapy, by Route of Administration USD Million (2017-2022)
  • Table 54. China Anticoagulation Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 55. China Anticoagulation Therapy, by End-user USD Million (2017-2022)
  • Table 56. China Anticoagulation Therapy, by Drug Class USD Million (2017-2022)
  • Table 57. Japan Anticoagulation Therapy, by Application USD Million (2017-2022)
  • Table 58. Japan Anticoagulation Therapy, by Route of Administration USD Million (2017-2022)
  • Table 59. Japan Anticoagulation Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 60. Japan Anticoagulation Therapy, by End-user USD Million (2017-2022)
  • Table 61. Japan Anticoagulation Therapy, by Drug Class USD Million (2017-2022)
  • Table 62. India Anticoagulation Therapy, by Application USD Million (2017-2022)
  • Table 63. India Anticoagulation Therapy, by Route of Administration USD Million (2017-2022)
  • Table 64. India Anticoagulation Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 65. India Anticoagulation Therapy, by End-user USD Million (2017-2022)
  • Table 66. India Anticoagulation Therapy, by Drug Class USD Million (2017-2022)
  • Table 67. South Korea Anticoagulation Therapy, by Application USD Million (2017-2022)
  • Table 68. South Korea Anticoagulation Therapy, by Route of Administration USD Million (2017-2022)
  • Table 69. South Korea Anticoagulation Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 70. South Korea Anticoagulation Therapy, by End-user USD Million (2017-2022)
  • Table 71. South Korea Anticoagulation Therapy, by Drug Class USD Million (2017-2022)
  • Table 72. Taiwan Anticoagulation Therapy, by Application USD Million (2017-2022)
  • Table 73. Taiwan Anticoagulation Therapy, by Route of Administration USD Million (2017-2022)
  • Table 74. Taiwan Anticoagulation Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 75. Taiwan Anticoagulation Therapy, by End-user USD Million (2017-2022)
  • Table 76. Taiwan Anticoagulation Therapy, by Drug Class USD Million (2017-2022)
  • Table 77. Australia Anticoagulation Therapy, by Application USD Million (2017-2022)
  • Table 78. Australia Anticoagulation Therapy, by Route of Administration USD Million (2017-2022)
  • Table 79. Australia Anticoagulation Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 80. Australia Anticoagulation Therapy, by End-user USD Million (2017-2022)
  • Table 81. Australia Anticoagulation Therapy, by Drug Class USD Million (2017-2022)
  • Table 82. Rest of Asia-Pacific Anticoagulation Therapy, by Application USD Million (2017-2022)
  • Table 83. Rest of Asia-Pacific Anticoagulation Therapy, by Route of Administration USD Million (2017-2022)
  • Table 84. Rest of Asia-Pacific Anticoagulation Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 85. Rest of Asia-Pacific Anticoagulation Therapy, by End-user USD Million (2017-2022)
  • Table 86. Rest of Asia-Pacific Anticoagulation Therapy, by Drug Class USD Million (2017-2022)
  • Table 87. Europe Anticoagulation Therapy, by Country USD Million (2017-2022)
  • Table 88. Europe Anticoagulation Therapy, by Application USD Million (2017-2022)
  • Table 89. Europe Anticoagulation Therapy, by Route of Administration USD Million (2017-2022)
  • Table 90. Europe Anticoagulation Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 91. Europe Anticoagulation Therapy, by End-user USD Million (2017-2022)
  • Table 92. Europe Anticoagulation Therapy, by Drug Class USD Million (2017-2022)
  • Table 93. Germany Anticoagulation Therapy, by Application USD Million (2017-2022)
  • Table 94. Germany Anticoagulation Therapy, by Route of Administration USD Million (2017-2022)
  • Table 95. Germany Anticoagulation Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 96. Germany Anticoagulation Therapy, by End-user USD Million (2017-2022)
  • Table 97. Germany Anticoagulation Therapy, by Drug Class USD Million (2017-2022)
  • Table 98. France Anticoagulation Therapy, by Application USD Million (2017-2022)
  • Table 99. France Anticoagulation Therapy, by Route of Administration USD Million (2017-2022)
  • Table 100. France Anticoagulation Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 101. France Anticoagulation Therapy, by End-user USD Million (2017-2022)
  • Table 102. France Anticoagulation Therapy, by Drug Class USD Million (2017-2022)
  • Table 103. Italy Anticoagulation Therapy, by Application USD Million (2017-2022)
  • Table 104. Italy Anticoagulation Therapy, by Route of Administration USD Million (2017-2022)
  • Table 105. Italy Anticoagulation Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 106. Italy Anticoagulation Therapy, by End-user USD Million (2017-2022)
  • Table 107. Italy Anticoagulation Therapy, by Drug Class USD Million (2017-2022)
  • Table 108. United Kingdom Anticoagulation Therapy, by Application USD Million (2017-2022)
  • Table 109. United Kingdom Anticoagulation Therapy, by Route of Administration USD Million (2017-2022)
  • Table 110. United Kingdom Anticoagulation Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 111. United Kingdom Anticoagulation Therapy, by End-user USD Million (2017-2022)
  • Table 112. United Kingdom Anticoagulation Therapy, by Drug Class USD Million (2017-2022)
  • Table 113. Netherlands Anticoagulation Therapy, by Application USD Million (2017-2022)
  • Table 114. Netherlands Anticoagulation Therapy, by Route of Administration USD Million (2017-2022)
  • Table 115. Netherlands Anticoagulation Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 116. Netherlands Anticoagulation Therapy, by End-user USD Million (2017-2022)
  • Table 117. Netherlands Anticoagulation Therapy, by Drug Class USD Million (2017-2022)
  • Table 118. Rest of Europe Anticoagulation Therapy, by Application USD Million (2017-2022)
  • Table 119. Rest of Europe Anticoagulation Therapy, by Route of Administration USD Million (2017-2022)
  • Table 120. Rest of Europe Anticoagulation Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 121. Rest of Europe Anticoagulation Therapy, by End-user USD Million (2017-2022)
  • Table 122. Rest of Europe Anticoagulation Therapy, by Drug Class USD Million (2017-2022)
  • Table 123. MEA Anticoagulation Therapy, by Country USD Million (2017-2022)
  • Table 124. MEA Anticoagulation Therapy, by Application USD Million (2017-2022)
  • Table 125. MEA Anticoagulation Therapy, by Route of Administration USD Million (2017-2022)
  • Table 126. MEA Anticoagulation Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 127. MEA Anticoagulation Therapy, by End-user USD Million (2017-2022)
  • Table 128. MEA Anticoagulation Therapy, by Drug Class USD Million (2017-2022)
  • Table 129. Middle East Anticoagulation Therapy, by Application USD Million (2017-2022)
  • Table 130. Middle East Anticoagulation Therapy, by Route of Administration USD Million (2017-2022)
  • Table 131. Middle East Anticoagulation Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 132. Middle East Anticoagulation Therapy, by End-user USD Million (2017-2022)
  • Table 133. Middle East Anticoagulation Therapy, by Drug Class USD Million (2017-2022)
  • Table 134. Africa Anticoagulation Therapy, by Application USD Million (2017-2022)
  • Table 135. Africa Anticoagulation Therapy, by Route of Administration USD Million (2017-2022)
  • Table 136. Africa Anticoagulation Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 137. Africa Anticoagulation Therapy, by End-user USD Million (2017-2022)
  • Table 138. Africa Anticoagulation Therapy, by Drug Class USD Million (2017-2022)
  • Table 139. North America Anticoagulation Therapy, by Country USD Million (2017-2022)
  • Table 140. North America Anticoagulation Therapy, by Application USD Million (2017-2022)
  • Table 141. North America Anticoagulation Therapy, by Route of Administration USD Million (2017-2022)
  • Table 142. North America Anticoagulation Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 143. North America Anticoagulation Therapy, by End-user USD Million (2017-2022)
  • Table 144. North America Anticoagulation Therapy, by Drug Class USD Million (2017-2022)
  • Table 145. United States Anticoagulation Therapy, by Application USD Million (2017-2022)
  • Table 146. United States Anticoagulation Therapy, by Route of Administration USD Million (2017-2022)
  • Table 147. United States Anticoagulation Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 148. United States Anticoagulation Therapy, by End-user USD Million (2017-2022)
  • Table 149. United States Anticoagulation Therapy, by Drug Class USD Million (2017-2022)
  • Table 150. Canada Anticoagulation Therapy, by Application USD Million (2017-2022)
  • Table 151. Canada Anticoagulation Therapy, by Route of Administration USD Million (2017-2022)
  • Table 152. Canada Anticoagulation Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 153. Canada Anticoagulation Therapy, by End-user USD Million (2017-2022)
  • Table 154. Canada Anticoagulation Therapy, by Drug Class USD Million (2017-2022)
  • Table 155. Mexico Anticoagulation Therapy, by Application USD Million (2017-2022)
  • Table 156. Mexico Anticoagulation Therapy, by Route of Administration USD Million (2017-2022)
  • Table 157. Mexico Anticoagulation Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 158. Mexico Anticoagulation Therapy, by End-user USD Million (2017-2022)
  • Table 159. Mexico Anticoagulation Therapy, by Drug Class USD Million (2017-2022)
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Company Basic Information, Sales Area and Its Competitors
  • Table 171. Company Basic Information, Sales Area and Its Competitors
  • Table 172. Anticoagulation Therapy: by Application(USD Million)
  • Table 173. Anticoagulation Therapy Venous Thromboembolism , by Region USD Million (2023-2028)
  • Table 174. Anticoagulation Therapy Deep Vein Thrombosis , by Region USD Million (2023-2028)
  • Table 175. Anticoagulation Therapy Coronary Artery Disease , by Region USD Million (2023-2028)
  • Table 176. Anticoagulation Therapy Heart Attack , by Region USD Million (2023-2028)
  • Table 177. Anticoagulation Therapy: by Route of Administration(USD Million)
  • Table 178. Anticoagulation Therapy Oral , by Region USD Million (2023-2028)
  • Table 179. Anticoagulation Therapy Parenteral , by Region USD Million (2023-2028)
  • Table 180. Anticoagulation Therapy: by Distribution Channel(USD Million)
  • Table 181. Anticoagulation Therapy Hospital Pharmacies , by Region USD Million (2023-2028)
  • Table 182. Anticoagulation Therapy Retail Pharmacies , by Region USD Million (2023-2028)
  • Table 183. Anticoagulation Therapy Online , by Region USD Million (2023-2028)
  • Table 184. Anticoagulation Therapy Others , by Region USD Million (2023-2028)
  • Table 185. Anticoagulation Therapy: by End-user(USD Million)
  • Table 186. Anticoagulation Therapy Hospitals , by Region USD Million (2023-2028)
  • Table 187. Anticoagulation Therapy Clinics , by Region USD Million (2023-2028)
  • Table 188. Anticoagulation Therapy Homecare , by Region USD Million (2023-2028)
  • Table 189. Anticoagulation Therapy Ambulatory Surgical Centres , by Region USD Million (2023-2028)
  • Table 190. Anticoagulation Therapy Others , by Region USD Million (2023-2028)
  • Table 191. Anticoagulation Therapy: by Drug Class(USD Million)
  • Table 192. Anticoagulation Therapy Novel Oral Anticoagulants (NOACs) , by Region USD Million (2023-2028)
  • Table 193. Anticoagulation Therapy Heparin & LMWH , by Region USD Million (2023-2028)
  • Table 194. Anticoagulation Therapy Vitamin K Antagonists , by Region USD Million (2023-2028)
  • Table 195. Anticoagulation Therapy Others , by Region USD Million (2023-2028)
  • Table 196. South America Anticoagulation Therapy, by Country USD Million (2023-2028)
  • Table 197. South America Anticoagulation Therapy, by Application USD Million (2023-2028)
  • Table 198. South America Anticoagulation Therapy, by Route of Administration USD Million (2023-2028)
  • Table 199. South America Anticoagulation Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 200. South America Anticoagulation Therapy, by End-user USD Million (2023-2028)
  • Table 201. South America Anticoagulation Therapy, by Drug Class USD Million (2023-2028)
  • Table 202. Brazil Anticoagulation Therapy, by Application USD Million (2023-2028)
  • Table 203. Brazil Anticoagulation Therapy, by Route of Administration USD Million (2023-2028)
  • Table 204. Brazil Anticoagulation Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 205. Brazil Anticoagulation Therapy, by End-user USD Million (2023-2028)
  • Table 206. Brazil Anticoagulation Therapy, by Drug Class USD Million (2023-2028)
  • Table 207. Argentina Anticoagulation Therapy, by Application USD Million (2023-2028)
  • Table 208. Argentina Anticoagulation Therapy, by Route of Administration USD Million (2023-2028)
  • Table 209. Argentina Anticoagulation Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 210. Argentina Anticoagulation Therapy, by End-user USD Million (2023-2028)
  • Table 211. Argentina Anticoagulation Therapy, by Drug Class USD Million (2023-2028)
  • Table 212. Rest of South America Anticoagulation Therapy, by Application USD Million (2023-2028)
  • Table 213. Rest of South America Anticoagulation Therapy, by Route of Administration USD Million (2023-2028)
  • Table 214. Rest of South America Anticoagulation Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 215. Rest of South America Anticoagulation Therapy, by End-user USD Million (2023-2028)
  • Table 216. Rest of South America Anticoagulation Therapy, by Drug Class USD Million (2023-2028)
  • Table 217. Asia Pacific Anticoagulation Therapy, by Country USD Million (2023-2028)
  • Table 218. Asia Pacific Anticoagulation Therapy, by Application USD Million (2023-2028)
  • Table 219. Asia Pacific Anticoagulation Therapy, by Route of Administration USD Million (2023-2028)
  • Table 220. Asia Pacific Anticoagulation Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 221. Asia Pacific Anticoagulation Therapy, by End-user USD Million (2023-2028)
  • Table 222. Asia Pacific Anticoagulation Therapy, by Drug Class USD Million (2023-2028)
  • Table 223. China Anticoagulation Therapy, by Application USD Million (2023-2028)
  • Table 224. China Anticoagulation Therapy, by Route of Administration USD Million (2023-2028)
  • Table 225. China Anticoagulation Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 226. China Anticoagulation Therapy, by End-user USD Million (2023-2028)
  • Table 227. China Anticoagulation Therapy, by Drug Class USD Million (2023-2028)
  • Table 228. Japan Anticoagulation Therapy, by Application USD Million (2023-2028)
  • Table 229. Japan Anticoagulation Therapy, by Route of Administration USD Million (2023-2028)
  • Table 230. Japan Anticoagulation Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 231. Japan Anticoagulation Therapy, by End-user USD Million (2023-2028)
  • Table 232. Japan Anticoagulation Therapy, by Drug Class USD Million (2023-2028)
  • Table 233. India Anticoagulation Therapy, by Application USD Million (2023-2028)
  • Table 234. India Anticoagulation Therapy, by Route of Administration USD Million (2023-2028)
  • Table 235. India Anticoagulation Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 236. India Anticoagulation Therapy, by End-user USD Million (2023-2028)
  • Table 237. India Anticoagulation Therapy, by Drug Class USD Million (2023-2028)
  • Table 238. South Korea Anticoagulation Therapy, by Application USD Million (2023-2028)
  • Table 239. South Korea Anticoagulation Therapy, by Route of Administration USD Million (2023-2028)
  • Table 240. South Korea Anticoagulation Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 241. South Korea Anticoagulation Therapy, by End-user USD Million (2023-2028)
  • Table 242. South Korea Anticoagulation Therapy, by Drug Class USD Million (2023-2028)
  • Table 243. Taiwan Anticoagulation Therapy, by Application USD Million (2023-2028)
  • Table 244. Taiwan Anticoagulation Therapy, by Route of Administration USD Million (2023-2028)
  • Table 245. Taiwan Anticoagulation Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 246. Taiwan Anticoagulation Therapy, by End-user USD Million (2023-2028)
  • Table 247. Taiwan Anticoagulation Therapy, by Drug Class USD Million (2023-2028)
  • Table 248. Australia Anticoagulation Therapy, by Application USD Million (2023-2028)
  • Table 249. Australia Anticoagulation Therapy, by Route of Administration USD Million (2023-2028)
  • Table 250. Australia Anticoagulation Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 251. Australia Anticoagulation Therapy, by End-user USD Million (2023-2028)
  • Table 252. Australia Anticoagulation Therapy, by Drug Class USD Million (2023-2028)
  • Table 253. Rest of Asia-Pacific Anticoagulation Therapy, by Application USD Million (2023-2028)
  • Table 254. Rest of Asia-Pacific Anticoagulation Therapy, by Route of Administration USD Million (2023-2028)
  • Table 255. Rest of Asia-Pacific Anticoagulation Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 256. Rest of Asia-Pacific Anticoagulation Therapy, by End-user USD Million (2023-2028)
  • Table 257. Rest of Asia-Pacific Anticoagulation Therapy, by Drug Class USD Million (2023-2028)
  • Table 258. Europe Anticoagulation Therapy, by Country USD Million (2023-2028)
  • Table 259. Europe Anticoagulation Therapy, by Application USD Million (2023-2028)
  • Table 260. Europe Anticoagulation Therapy, by Route of Administration USD Million (2023-2028)
  • Table 261. Europe Anticoagulation Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 262. Europe Anticoagulation Therapy, by End-user USD Million (2023-2028)
  • Table 263. Europe Anticoagulation Therapy, by Drug Class USD Million (2023-2028)
  • Table 264. Germany Anticoagulation Therapy, by Application USD Million (2023-2028)
  • Table 265. Germany Anticoagulation Therapy, by Route of Administration USD Million (2023-2028)
  • Table 266. Germany Anticoagulation Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 267. Germany Anticoagulation Therapy, by End-user USD Million (2023-2028)
  • Table 268. Germany Anticoagulation Therapy, by Drug Class USD Million (2023-2028)
  • Table 269. France Anticoagulation Therapy, by Application USD Million (2023-2028)
  • Table 270. France Anticoagulation Therapy, by Route of Administration USD Million (2023-2028)
  • Table 271. France Anticoagulation Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 272. France Anticoagulation Therapy, by End-user USD Million (2023-2028)
  • Table 273. France Anticoagulation Therapy, by Drug Class USD Million (2023-2028)
  • Table 274. Italy Anticoagulation Therapy, by Application USD Million (2023-2028)
  • Table 275. Italy Anticoagulation Therapy, by Route of Administration USD Million (2023-2028)
  • Table 276. Italy Anticoagulation Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 277. Italy Anticoagulation Therapy, by End-user USD Million (2023-2028)
  • Table 278. Italy Anticoagulation Therapy, by Drug Class USD Million (2023-2028)
  • Table 279. United Kingdom Anticoagulation Therapy, by Application USD Million (2023-2028)
  • Table 280. United Kingdom Anticoagulation Therapy, by Route of Administration USD Million (2023-2028)
  • Table 281. United Kingdom Anticoagulation Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 282. United Kingdom Anticoagulation Therapy, by End-user USD Million (2023-2028)
  • Table 283. United Kingdom Anticoagulation Therapy, by Drug Class USD Million (2023-2028)
  • Table 284. Netherlands Anticoagulation Therapy, by Application USD Million (2023-2028)
  • Table 285. Netherlands Anticoagulation Therapy, by Route of Administration USD Million (2023-2028)
  • Table 286. Netherlands Anticoagulation Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 287. Netherlands Anticoagulation Therapy, by End-user USD Million (2023-2028)
  • Table 288. Netherlands Anticoagulation Therapy, by Drug Class USD Million (2023-2028)
  • Table 289. Rest of Europe Anticoagulation Therapy, by Application USD Million (2023-2028)
  • Table 290. Rest of Europe Anticoagulation Therapy, by Route of Administration USD Million (2023-2028)
  • Table 291. Rest of Europe Anticoagulation Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 292. Rest of Europe Anticoagulation Therapy, by End-user USD Million (2023-2028)
  • Table 293. Rest of Europe Anticoagulation Therapy, by Drug Class USD Million (2023-2028)
  • Table 294. MEA Anticoagulation Therapy, by Country USD Million (2023-2028)
  • Table 295. MEA Anticoagulation Therapy, by Application USD Million (2023-2028)
  • Table 296. MEA Anticoagulation Therapy, by Route of Administration USD Million (2023-2028)
  • Table 297. MEA Anticoagulation Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 298. MEA Anticoagulation Therapy, by End-user USD Million (2023-2028)
  • Table 299. MEA Anticoagulation Therapy, by Drug Class USD Million (2023-2028)
  • Table 300. Middle East Anticoagulation Therapy, by Application USD Million (2023-2028)
  • Table 301. Middle East Anticoagulation Therapy, by Route of Administration USD Million (2023-2028)
  • Table 302. Middle East Anticoagulation Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 303. Middle East Anticoagulation Therapy, by End-user USD Million (2023-2028)
  • Table 304. Middle East Anticoagulation Therapy, by Drug Class USD Million (2023-2028)
  • Table 305. Africa Anticoagulation Therapy, by Application USD Million (2023-2028)
  • Table 306. Africa Anticoagulation Therapy, by Route of Administration USD Million (2023-2028)
  • Table 307. Africa Anticoagulation Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 308. Africa Anticoagulation Therapy, by End-user USD Million (2023-2028)
  • Table 309. Africa Anticoagulation Therapy, by Drug Class USD Million (2023-2028)
  • Table 310. North America Anticoagulation Therapy, by Country USD Million (2023-2028)
  • Table 311. North America Anticoagulation Therapy, by Application USD Million (2023-2028)
  • Table 312. North America Anticoagulation Therapy, by Route of Administration USD Million (2023-2028)
  • Table 313. North America Anticoagulation Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 314. North America Anticoagulation Therapy, by End-user USD Million (2023-2028)
  • Table 315. North America Anticoagulation Therapy, by Drug Class USD Million (2023-2028)
  • Table 316. United States Anticoagulation Therapy, by Application USD Million (2023-2028)
  • Table 317. United States Anticoagulation Therapy, by Route of Administration USD Million (2023-2028)
  • Table 318. United States Anticoagulation Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 319. United States Anticoagulation Therapy, by End-user USD Million (2023-2028)
  • Table 320. United States Anticoagulation Therapy, by Drug Class USD Million (2023-2028)
  • Table 321. Canada Anticoagulation Therapy, by Application USD Million (2023-2028)
  • Table 322. Canada Anticoagulation Therapy, by Route of Administration USD Million (2023-2028)
  • Table 323. Canada Anticoagulation Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 324. Canada Anticoagulation Therapy, by End-user USD Million (2023-2028)
  • Table 325. Canada Anticoagulation Therapy, by Drug Class USD Million (2023-2028)
  • Table 326. Mexico Anticoagulation Therapy, by Application USD Million (2023-2028)
  • Table 327. Mexico Anticoagulation Therapy, by Route of Administration USD Million (2023-2028)
  • Table 328. Mexico Anticoagulation Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 329. Mexico Anticoagulation Therapy, by End-user USD Million (2023-2028)
  • Table 330. Mexico Anticoagulation Therapy, by Drug Class USD Million (2023-2028)
  • Table 331. Research Programs/Design for This Report
  • Table 332. Key Data Information from Secondary Sources
  • Table 333. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Anticoagulation Therapy: by Application USD Million (2017-2022)
  • Figure 5. Global Anticoagulation Therapy: by Route of Administration USD Million (2017-2022)
  • Figure 6. Global Anticoagulation Therapy: by Distribution Channel USD Million (2017-2022)
  • Figure 7. Global Anticoagulation Therapy: by End-user USD Million (2017-2022)
  • Figure 8. Global Anticoagulation Therapy: by Drug Class USD Million (2017-2022)
  • Figure 9. South America Anticoagulation Therapy Share (%), by Country
  • Figure 10. Asia Pacific Anticoagulation Therapy Share (%), by Country
  • Figure 11. Europe Anticoagulation Therapy Share (%), by Country
  • Figure 12. MEA Anticoagulation Therapy Share (%), by Country
  • Figure 13. North America Anticoagulation Therapy Share (%), by Country
  • Figure 14. Global Anticoagulation Therapy share by Players 2022 (%)
  • Figure 15. Global Anticoagulation Therapy share by Players (Top 3) 2022(%)
  • Figure 16. Global Anticoagulation Therapy share by Players (Top 5) 2022(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 19. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2022
  • Figure 20. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Pfizer, Inc. (United States) Revenue: by Geography 2022
  • Figure 22. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 23. Abbott Laboratories (United States) Revenue: by Geography 2022
  • Figure 24. Baxter International Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Baxter International Inc. (United States) Revenue: by Geography 2022
  • Figure 26. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 27. AstraZeneca plc (United Kingdom) Revenue: by Geography 2022
  • Figure 28. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 29. Bayer AG (Germany) Revenue: by Geography 2022
  • Figure 30. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Merck & Co., Inc. (United States) Revenue: by Geography 2022
  • Figure 32. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 33. Eli Lilly and Company (United States) Revenue: by Geography 2022
  • Figure 34. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 35. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2022
  • Figure 36. Genentech Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Genentech Inc. (United States) Revenue: by Geography 2022
  • Figure 38. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 39. Sanofi S.A. (France) Revenue: by Geography 2022
  • Figure 40. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 41. Novartis International AG (Switzerland) Revenue: by Geography 2022
  • Figure 42. Global Anticoagulation Therapy: by Application USD Million (2023-2028)
  • Figure 43. Global Anticoagulation Therapy: by Route of Administration USD Million (2023-2028)
  • Figure 44. Global Anticoagulation Therapy: by Distribution Channel USD Million (2023-2028)
  • Figure 45. Global Anticoagulation Therapy: by End-user USD Million (2023-2028)
  • Figure 46. Global Anticoagulation Therapy: by Drug Class USD Million (2023-2028)
  • Figure 47. South America Anticoagulation Therapy Share (%), by Country
  • Figure 48. Asia Pacific Anticoagulation Therapy Share (%), by Country
  • Figure 49. Europe Anticoagulation Therapy Share (%), by Country
  • Figure 50. MEA Anticoagulation Therapy Share (%), by Country
  • Figure 51. North America Anticoagulation Therapy Share (%), by Country
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline plc (United Kingdom)
  • Pfizer, Inc. (United States)
  • Abbott Laboratories (United States)
  • Baxter International Inc. (United States)
  • AstraZeneca plc (United Kingdom)
  • Bayer AG (Germany)
  • Merck & Co., Inc. (United States)
  • Eli Lilly and Company (United States)
  • Bristol-Myers Squibb Company (United States)
  • Genentech Inc. (United States)
  • Sanofi S.A. (France)
  • Novartis International AG (Switzerland)
Additional players considered in the study are as follows:
BioVascular Inc. (United Kingdom) , C.H. Boehringer Sohn AG & Ko. KG (Germany)
Select User Access Type

Key Highlights of Report


May 2023 213 Pages 50 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Anticoagulation Therapy Quantitative research analysis
Global Anticoagulation Therapy Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Increased Prevalence of Venous Thromboembolism, Deep Vein Thrombosis and Heart Diseases among People " is seen as one of major growth factors of Anticoagulation Therapy Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
The Anticoagulation Therapy market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global Anticoagulation Therapy Report?

Have a Query? Click Here

Other Related Reports

Toxoid Vaccines Comprehensive Study by Type (Monovalent Tetanus Toxoid (TT), Diphtheria, Tetanus, Pertussis (DTaP), Diphtheria and Tetanus (DT)), Forms (Quadrivalent, Pentavalent, Hexavalent), End-us...
$ 3450
Ophthalmoplegia Comprehensive Study by Type (External Ophthalmoplegia, Internuclear Ophthalmoplegia), Application (Telemedicine Platforms, Assistive Technology Application, Low Vision Aid Apps), End ...
$ 3500
Brain Tumor Diagnosis and Treatments Comprehensive Study by Type (Primary Brain Tumor (Meningioma, Gliomas, Astrocytomas, Pituitary Tumors, Other Primary Brain Tumors), Secondary Brain Tumor), Applic...
$ 3750
Tuberculosis Treatment Drugs Comprehensive Study by Type (Active TB, Latent TB), Application (Hospital, Clinic, Durgstore), Drugs (First Line anti-TB Drugs, Second Line anti- TB Drugs) Players and Re...
$ 3500
Acute Disease Comprehensive Study by Type (Acute minor illness (self-limiting), Acute major illness (self-limiting or requiring treatment), Acute presentation of existing major illness (acute exacerb...
$ 3650
Bone Growth Stimulator Comprehensive Study by Application (Spinal Fusion, Delay Union & Non-union Bone Fracture, Oral-maxillofacial, Other Applications), Stimulators (Internal Bone Growth Stimulators...
$ 3750